Septerna Prices Upsized Initial Public Offering

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to its Board of Directors

Maze Therapeutics to Present New Data Supporting Advancement of MZE829 and MZE782 Clinical Development at American Society of Nephrology's Kidney Week and American Society of Human Genetics Annual Meeting.